View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2017	May 04, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Trading Symbol	CBIO
Entity Registrant Name	CATALYST BIOSCIENCES, INC.
Entity Central Index Key	0001124105
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		4,260,561

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 14,533	$ 10,264
Short-term investments		6,800
Restricted cash	12,735	19,468
Accounts receivable	227	31
Prepaid and other current assets	1,041	958
Total current assets	28,536	37,521
Restricted cash, noncurrent	125	125
Property and equipment, net	399	444
Total assets	29,060	38,090
Current liabilities:
Accounts payable	899	837
Accrued compensation	645	596
Other accrued liabilities	730	805
Deferred revenue, current portion	259	283
Deferred rent, current portion	40	41
Redeemable convertible notes	12,651	19,403
Total current liabilities	15,224	21,965
Deferred revenue, noncurrent portion		47
Deferred rent, noncurrent portion		7
Total liabilities	15,224	22,019
Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000,000 shares and no shares authorized and outstanding at both March 31, 2017 and December 31, 2016
Common stock, $0.001 par value, 100,000,000 shares authorized; 1,000,036 and 801,756 shares issued and outstanding at March 31, 2017 and December 31, 2016	2	1
Additional paid-in capital	165,954	164,053
Accumulated other comprehensive income (loss)		(1)
Accumulated deficit	(152,120)	(147,982)
Total stockholders’ equity	13,836	16,071
Total liabilities and stockholders’ equity	$ 29,060	$ 38,090

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	1,000,036	801,756
Common stock, shares outstanding	1,000,036	801,756

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Statement [Abstract]
Contract revenue	$ 271	$ 109
Operating expenses:
Research and development	2,061	2,286
General and administrative	2,381	2,395
Total operating expenses	4,442	4,681
Loss from operations	(4,171)	(4,572)
Interest and other income, net	33	980
Net loss	$ (4,138)	$ (3,592)
Net loss per common share, basic and diluted	$ (4.57)	$ (4.71)
Shares used to compute net loss per common share, basic and diluted	906,048	762,007

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (4,138)	$ (3,592)
Other comprehensive income (loss):
Unrealized gain on available-for-sale securities	1	3
Total comprehensive loss	$ (4,137)	$ (3,589)

Condensed Consolidated Statement of Stockholders Equity (Unaudited) - 3 months ended Mar. 31, 2017 - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income	Accumulated Deficit
Balance at Dec. 31, 2016	$ 16,071	$ 1	$ 164,053	$ (1)	$ (147,982)
Balance (in shares) at Dec. 31, 2016		801,756
Stock-based compensation expense	120		120
Issuance of stock, value	1,782	$ 1	1,781
Issuance of stock, shares		198,280
Unrealized gain on available-for-sale securities	1			$ 1
Net loss	(4,138)				(4,138)
Balance at Mar. 31, 2017	$ 13,836	$ 2	$ 165,954		$ (152,120)
Balance (in shares) at Mar. 31, 2017		1,000,036

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Operating Activities
Net loss	$ (4,138,000)	$ (3,592,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	120,000	153,000
Depreciation and amortization	48,000	105,000
Gain on extinguishment of redeemable convertible notes	0	(85,000)
Change in fair value of derivative liability		(875,000)
Changes in operating assets and liabilities:
Accounts receivable	(196,000)	44,000
Prepaid and other current assets	(83,000)	281,000
Accounts payable	62,000	(222,000)
Accrued compensation and other accrued liabilities	(26,000)	(441,000)
Deferred rent	(8,000)	(3,000)
Deferred revenue	(71,000)	(109,000)
Net cash flows used in operating activities	(4,292,000)	(4,744,000)
Investing Activities
Proceeds from maturities of short-term investments	6,801,000
Purchase of investments		(3,682,000)
Change in restricted cash	(19,000)	(1,000)
Purchases of property and equipment	(3,000)	(89,000)
Net cash flows (used in) provided by investing activities	6,779,000	(3,772,000)
Financing Activities
Release of restricted cash due to conversion and redemption of redeemable convertible notes	6,752,000	2,807,000
Payments for the redemption of redeemable convertible notes	(6,752,000)	(2,807,000)
Proceeds from issuance of common stock, net of issuance costs	1,782,000
Net cash flows provided by financing activities	1,782,000
Net (decrease) increase in cash and cash equivalents	4,269,000	(8,516,000)
Cash and cash equivalents at beginning of period	10,264,000	29,096,000
Cash and equivalents at end of period	14,533,000	20,580,000
Supplemental Disclosure of Non-Cash Investing and Financing Information:
Unrealized Gain (Loss) on investments	$ 1,000	$ 3,000

Nature of Operations

3 Months Ended

Mar. 31, 2017

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Nature of Operations

1.	Nature of Operations

Catalyst Biosciences, Inc. (the “Company” or “Catalyst”), is a clinical-stage biotechnology company focused on developing novel medicines to address hematology indications, including the treatment of hemophilia. Its facilities are in South San Francisco, California and it operates in one segment.

Prior to August 20, 2015, the name of the Company was Targacept, Inc. (“Targacept”). On August 20, 2015, Targacept completed its business combination with Catalyst Bio, Inc. (“Catalyst Bio”) by and among Targacept, Talos Merger Sub, Inc. (“Merger Sub”) and Catalyst Bio, pursuant to which Merger Sub merged with and into Catalyst Bio, with Catalyst Bio surviving as a wholly-owned subsidiary of Targacept (the “Merger”) and changed its name from Targacept, Inc. to Catalyst Biosciences, Inc. Prior to and in connection with the Merger, the Company paid a dividend to the Targacept holders consisting of cash and non-interest bearing redeemable convertible notes (the “Pre-Closing Dividend”), see Note 5 for further detail.

On February 10, 2017, the Company effected a reverse stock split of its common stock at a ratio of 1-for-15 (“2017 Reverse Stock Split”). The 2017 Reverse Stock Split was approved by the Company’s stockholders at a special meeting of stockholders held on February 2, 2017. As a result of the 2017 Reverse Stock Split, each 15 pre-split shares of common stock outstanding were automatically combined into one new share of common stock, and the number of outstanding shares of common stock on the date of the split was reduced from approximately 13.0 million shares to approximately 868,000 shares. Unless otherwise specified, all share and per share amounts in these notes and the accompanying consolidated financial statements are reported on a post-stock split basis for all periods presented.

On April 3, 2017, under the Company’s at the market offering program with JonesTrading Institutional Services LLC (“JonesTrading”), the Company sold an aggregate of 241,600 shares of its common stock for approximately $3.5 million of net proceeds. Following such sales, the Company has no more common stock available for sale under the program.

On April 12, 2017, the Company issued and sold in a registered, underwritten public offering an aggregate of (i) 1,470,000 shares of common stock (including 540,000 shares of common stock sold pursuant to the exercise of the Underwriter’s overallotment option), (ii) 13,350 shares of Series A Preferred Stock, each convertible into 200 shares of common stock and (iii) warrants to purchase 2,070,000 shares of common stock at an exercise price of $5.50 per share (including 270,000 sold pursuant to the exercise of the underwriter’s overallotment option). The net proceeds to the Company, after deducting the underwriting discounts and commissions and offering expenses payable by the Company was approximately $18.7 million.

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.	Summary of Significant Accounting Policies

Basis of Presentation

The Company’s condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company’s financial information. These interim results and cash flows for any interim period are not necessarily indicative of the results to be expected for the full year.

The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the consolidated financial statements filed with the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 (“Annual Report”).

The Company’s significant accounting policies are included in “Part II - Item 8 - Financial Statements and Supplementary Data - Note 2 – Summary of Significant Accounting Policies” in the Company’s Annual Report. There have been no significant changes to these accounting policies during the first three months of 2017.

Fair Value Measurements

3 Months Ended

Mar. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value Measurements

3.	Fair Value Measurements

For a description of the fair value hierarchy and the Company’s fair value methodology, see “Part II - Item 8 - Financial Statements and Supplementary Data - Note 2 – Summary of Significant Accounting Policies” in the Company’s Annual Report. There were no significant changes in these methodologies during the three months ended March 31, 2017. As of March 31, 2017, the Company’s highly liquid money market funds included cash equivalents and restricted cash, including deposit in an escrow account and as of December 31, 2016, included cash equivalents, U.S. government agency securities and restricted cash, including deposit in an escrow account, these financial assets are valued using Level 1 inputs. There were no transfers in or out of Level 1 and Level 2 during the periods presented.

Liabilities that are measured at fair value consist of the derivative liability and is valued using Level 3 inputs. There were no transfers in or out of Level 3 during the periods presented.

As of March 31, 2017 and December 31, 2016 the fair value of the derivative liability was immaterial. The estimated reporting date fair value-based measurement of the derivative liability was calculated using the Black-Scholes valuation model.

The following tables present the fair value hierarchy for assets and liabilities measured at fair value on a recurring basis as of March 31, 2017 and December 31, 2016 (in thousands):

	March 31, 2017
	Level 1		Level 2		Level 3		Total
Financial assets:
Money market funds⁽¹⁾	$	14,619		—		—	$	14,619
Restricted cash (money market funds)⁽²⁾		12,860		—		—		12,860
Total financial assets	$	27,479	$	—	$	—	$	27,479

(1)	Included in Cash and Cash Equivalents on accompanying condensed consolidated balance sheets.

(2)	$12.7 million of restricted cash in the Indenture serves as full collateral for the redeemable convertible notes and $125,000 of restricted cash serves as collateral for the Company’s corporate credit card and deposit for its facility lease.

	December 31, 2016
	Level 1		Level 2		Level 3		Total
Financial assets:
Money market funds⁽¹⁾	$	10,156	$	—	$	—	$	10,156
Restricted cash (money market funds)⁽²⁾		19,593		—		—		19,593
U.S. government agency securities⁽³⁾		6,800		—		—		6,800
Total financial assets	$	36,549	$	—	$	—	$	36,549

(1)	Included in Cash and Cash Equivalents on accompanying condensed consolidated balance sheets.

(2)	$19.4 million of restricted cash in the Indenture serves as full collateral for the redeemable convertible notes and $125,000 of restricted cash serves as collateral for the Company’s corporate credit card and deposit for its facility lease.

(3)	Included in Short-Term Investments on accompanying condensed consolidated balance sheets.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Financial Instruments

3 Months Ended

Mar. 31, 2017

Investments All Other Investments [Abstract]

Financial Instruments

4.	Financial Instruments

Cash equivalents, restricted cash and short-term investments, all of which are classified as available-for-sale securities, consisted of the following (in thousands):

March 31, 2017	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Money market funds	$	14,619	$	—	$	—	$	14,619
Restricted cash (money market funds)		12,860		—		—		12,860
Total financial assets	$	27,479	$	—	$	—	$	27,479
Classified as:
Cash and cash equivalents							$	14,619
Restricted cash (money market funds)								12,860
							$	27,479

December 31, 2016	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
Money market funds	$	10,156	$	—	$	—		$	10,156
Restricted cash (money market funds)		19,593		—		—			19,593
Corporate notes		6,802		—		(2	)		6,800
Total financial assets	$	36,551	$	—	$	(2	)	$	36,549
Classified as:
Cash and cash equivalents								$	10,156
Restricted cash (money market funds)									19,593
Short-term investments									6,800
								$	36,549

There have been no significant realized gains or losses on available-for-sale securities for the periods presented. The carrying amounts of cash, accounts receivable and accounts payable approximate fair values due to the short-term maturity of these instruments.

Redeemable Convertible Notes

3 Months Ended

Mar. 31, 2017

Debt Disclosure [Abstract]

Redeemable Convertible Notes

5.	Redeemable Convertible Notes

On August 19, 2015, immediately prior to the Merger, the Company issued to Targacept stockholders non-interest bearing redeemable convertible notes (the “Notes”) in the aggregate principal amount of $37.0 million. The Notes do not bear interest. The principal amount of the Notes are convertible, at the option of each noteholder, into cash or into shares of the Company’s common stock at a conversion rate of $137.85 per share, and are payable in cash, if not previously redeemed or converted, at maturity on February 19, 2018, the 30-month anniversary of the closing of the issuance of the Notes.

In connection with the Pre-Closing Dividend, on August 19, 2015, Targacept entered into an indenture (the “Indenture”) with American Stock Transfer & Trust Company, LLC, as trustee, and an escrow agreement with American Stock Transfer & Trust Company, LLC and Delaware Trust Company, LLC, as escrow agent, under which $37.0 million, which represented the initial principal amount of the convertible notes, was deposited in a segregated escrow account for the benefit of the holders of the notes in order to facilitate the payment of the notes upon redemption or at maturity (the amount of such deposit together with interest accrued and capitalized thereon, the “Escrow Funds”). The Notes are the Company’s secured obligation, and the Indenture does not limit its other indebtedness, secured or unsecured.

Holders of the Notes may submit conversion notices, which are irrevocable, instructing the trustee to convert such Notes into shares of common stock at a conversion price of $137.85 per share. Following each conversion date, the Company will issue the number of whole shares of common stock issuable upon conversion as promptly as practicable (and in any event within 10 business days). The trustee will in turn release to the Company the respective amount of restricted cash to cover the stock issuance.

The conversion to common stock feature of the Notes was determined to be a derivative liability requiring bifurcation and separate accounting. The fair value of such conversion feature at issuance was determined to be $1.5 million. The bifurcation of the derivative liability from the estimated fair value of the Notes of $37.1 million at issuance resulted in a debt discount of $1.4 million. The Company elected to accrete the entire debt discount as interest expense immediately after the Merger. In addition, changes in the fair value of the derivative liability are being recorded within interest and other income in the consolidated statements of operations. The Company remeasures the derivative liability to fair value until the earlier of the conversion, redemption or maturity of the redeemable convertible notes.

As of March 31, 2017 and December 31, 2016, the fair value of the derivative liability was immaterial. The estimated reporting date fair value-based measurement of the derivative liability was calculated using the Black-Scholes valuation model.

The Company recognized no interest expense for both the three months ended March 31, 2017 and 2016, related to the amortization of the debt discount within interest expense on the Company’s consolidated statement of operations as the redeemable convertible notes are immediately fully redeemable at the option of the holders.

As of March 31, 2017, $24.1 million of the Notes were redeemed and $0.3 million of the Notes were converted into common stock. $6.7 million of the Notes were redeemed during the three months ended March 31, 2017. The Company recognized no gain on the extinguishment of Notes upon the redemption of the Notes during the three months ended March 31, 2017.

Stock Based Compensation

3 Months Ended

Mar. 31, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock Based Compensation

6.	Stock Based Compensation

The following table summarizes stock option activity under the Company’s equity incentive plans, including stock options granted to non-employees, and related information:

	Number of Shares Underlying Outstanding Options			Weighted- Average Exercise Price		Weighted-Average Remaining Contractual Term (Years)
Outstanding — December 31, 2016		140,990		$	127.56		3.93
Options granted		—
Options forfeited		(15,495	)	$	188.73
Outstanding — March 31, 2017		125,495		$	120.00		4.13
Exercisable — March 31, 2017		93,959		$	143.44		2.58
Vested and expected to vest — March 31, 2017		125,495		$	120.00		4.13

Valuation Assumptions

The Company estimated the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. This fair value is being amortized ratably over the requisite service periods of the awards, which is generally the vesting period. The fair value of employee stock options was estimated using the following weighted-average assumptions for the three months ended March 31, 2016:

	Three Months Ended March 31,
	2016
Employee Stock Options:
Risk-free interest rate		1.57	%
Expected term (in years)		6.04
Dividend yield		—
Volatility		73.28	%
Weighted-average fair value of stock options granted	$	21.15

Total stock-based compensation recognized was as follows (in thousands):

	Three Months Ended March 31,
	2017		2016
Research and development	$	20	$	50
General and administrative		100		103
Total stock-based compensation	$	120	$	153

As of March 31, 2017, 101,304 shares of common stock were available for future grant, 44,704 options to purchase shares of common stock were outstanding and the Company had unrecognized employee stock-based compensation expense of $1.0 million, related to unvested stock awards, which is expected to be recognized over an estimated weighted-average period of 2.36 years.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Collaborations

3 Months Ended

Mar. 31, 2017

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Collaborations

7.	Collaborations

Pfizer

On August 20, 2013, the Company and Pfizer signed an amendment to the Factor VIIa collaboration agreement in which the companies agreed to provide specific mutual releases and covenants and modify certain milestone payment schedules in the agreement.

On April 2, 2015, Pfizer notified the Company that it was exercising its right to terminate the research and license agreement effective June 1, 2015. The termination became effective 60 days after the Company’s receipt of the termination notice. On June 1, 2015, the license and certain rights under the research and license agreement terminated and reverted to the Company.

On December 8, 2016, the Company signed an agreement with Pfizer pursuant to which the parties terminated the research and license agreement that was signed on June 29, 2009. Pursuant to the new agreement, Pfizer granted the Company an exclusive license to Pfizer’s proprietary rights for manufacturing and processes that apply to Factor VIIa variants, CB 813a (marzeptacog alfa (activated)). Pfizer has also transferred and will transfer to the Company documentation related to the development, manufacturing and testing of the Products, including the Investigational New Drug (“IND”) application as well as the orphan drug designation.

As part of the new agreement, the Company agreed to make contingent cash payments to Pfizer in an aggregate amount equal to up to $17.5 million, payable upon the achievement of clinical, regulatory and commercial milestones. Following commercialization of any covered product, Pfizer would also receive a single-digit royalty on net product sales on a country-by-country basis for a predefined royalty term. No amounts have been paid to date under this new agreement.

ISU Abxis

On June 16, 2013, the Company signed a license and collaboration agreement with ISU Abxis, whereby the Company licensed its proprietary human Factor IX products to ISU Abxis for initial development in South Korea. Under the terms of the agreement, ISU Abxis is responsible for manufacturing, preclinical development activities and clinical development through completion of a proof-of-concept Phase 1/2 study in individuals with hemophilia B. The Company has the sole rights and responsibility for worldwide development, manufacture, and commercialization of Factor IX products after Phase 1/2 development. ISU Abxis may exercise its right of first refusal to acquire commercialization rights in South Korea, in which case they would be entitled to profit sharing on worldwide sales. ISU’s rights will also terminate if the Company enters into a license agreement with another party to develop, manufacture and commercialize Factor IX products in at least two major market territories.

ISU Abxis paid the Company an up-front signing fee of $1.75 million and is obligated to pay to the Company contingent milestone-based payments on the occurrence of certain defined development events, and reimbursement for a portion of the Company’s costs relating to intellectual property filings and maintenance thereof on products. The Company is obligated to pay ISU Abxis a percentage of all net profits it receives from collaboration products.

Contract revenue of $0.3 million and $0.1 million for the three months ended March 31, 2017 and 2016, respectively, reflected (i) the amortization of the up-front fee over the estimated period of the Company’s performance obligations under the agreement, which was assessed to be four years beginning in September 2013 when the agreement was executed and (ii) $0.2 million recorded in March 2017 for a milestone payment earned by the Company. The deferred revenue balance related to the ISU Abxis collaboration was $0.3 million and $0.6 million as of March 31, 2017 and 2016, respectively.

Net Loss per Share

3 Months Ended

Mar. 31, 2017

Earnings Per Share [Abstract]

Net Loss per Share

8.	Net Loss per Share

The following table sets forth the computation of the basic and diluted net loss per share during the three months ended March 31, 2017 and 2016 (in thousands, except share and per share data):

	Three Months Ended March 31,
	2017			2016
Net loss, basic and diluted	$	(4,138	)	$	(3,592	)
Weighted-average number of shares used in computing net loss per share, basic and diluted		906,048			762,007
Net loss per share, basic and diluted	$	(4.57	)	$	(4.71	)

Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities on an as-if converted basis that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:

	March 31,		December 31,
	2017		2016
Options to purchase common stock		125,495		140,990
Common stock warrants		12,039		12,063
Redeemable convertible notes		92,462		140,743
Total		229,996		293,796

Common Stock

3 Months Ended

Mar. 31, 2017

Equity [Abstract]

Common Stock

9.	Common Stock

On March 16, 2016, the Company signed a Capital on Demand^TM Sales Agreement with JonesTrading. In accordance with the terms of the sales agreement, the Company may offer and sell shares of its common stock having an aggregate offering price up to $6.5 million, subject to certain limitations, from time to time in one or more public offerings of the Company’s common stock, with JonesTrading acting as agent, in transactions pursuant to a shelf registration statement that was declared effective by the SEC on April 28, 2016.

The Company sold 198,280 shares of common stock in the open market at a weighted-average selling price of $9.55 per share, for net proceeds (net of commissions) of $1.8 million during the three months ended March 31, 2017, in the Capital on Demand^TM program. The Company charged approximately $0.1 million for JonesTrading commission against additional paid-in capital for the three months ended March 31, 2017.

Commitments and Contingencies

3 Months Ended

Mar. 31, 2017

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

10.	Commitments and Contingencies

Operating Leases

The Company leases office space for its corporate headquarters in South San Francisco, California. The lease will expire in February 2018.

Future minimum lease payments under all non-cancelable operating leases as of March 31, 2017, were as follows (in thousands):

	Minimum Lease Payments
2017		561
2018		125
Total future minimum lease payments		686

Manufacturing Agreements

On May 20, 2016, the Company entered into a development and manufacturing services agreement with CMC ICOS Biologics, Inc. (“CMC”), pursuant to which CMC will conduct manufacturing development and, upon successful development of the manufacturing process, manufacture the Company’s next-generation Factor VIIa variant marzeptacog alfa (activated) that the Company intends to use in its clinical trials. The Company has agreed to a total of $3.8 million in payments to CMC pursuant to the initial statement of work under the Agreement, subject to completion of applicable work stages. As of March 31, 2017, the Company was obligated to $2.1 million in payments to CMC remaining under the agreement.

Interest and Other Income

3 Months Ended

Mar. 31, 2017

Other Income And Expenses [Abstract]

Interest and Other Income

11. Interest and Other Income

As of March 31, 2017 and December 31, 2016, the fair value of the derivative liability was immaterial.

The following table shows the detail of other income/(expense), net for the three month periods ended March 31, 2017 and 2016 (in thousands):

	Three Months Ended March 31,
	2017		2016
Change in derivative liability	$	—	$	960
Other Income, net		33		20
Total Other Income/(expense), net	$	33	$	980

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent events On April 3, 2017, under the Company’s at the market offering program with JonesTrading, the Company sold an aggregate of 241,600 shares of its common stock for approximately $3.5 million of net proceeds. Following such sales, the Company has no more common stock available for sale under the program. On April 12, 2017, the Company issued and sold in a registered, underwritten public offering an aggregate of (i) 1,470,000 shares of common stock (including 540,000 shares of common stock sold pursuant to the exercise of the Underwriter’s overallotment option), (ii) 13,350 shares of Series A Preferred Stock, each convertible into 200 shares of common stock and (iii) warrants to purchase 2,070,000 shares of common stock at an exercise price of $5.50 per share (including 270,000 sold pursuant to the exercise of the Underwriter’s overallotment option). The net proceeds to the Company, after deducting the underwriting discounts and commissions and offering expenses payable by the Company was approximately $18.7 million. In connection with and following the Company’s underwritten public offering, certain holders of Series A Preferred Stock and warrants elected to convert or exercise such shares and warrants, respectively. In addition, subsequent to March 31, 2017, additional redeemable convertible notes were redeemed by the holders thereof. Accordingly, as of May 4, 2017, the Company had outstanding 4,260,561 shares of common stock, 5,750 shares of Series A Preferred Stock (convertible into an aggregate of 1,150,000 shares of common stock), warrants to purchase 2,041,075 shares of common stock at an exercise price of $5.50 per share, and options under the Company’s 2015 Stock Incentive Plan to purchase an aggregate of 44,670 shares of common stock at a weighted-average exercise price of $58.65 per share (in addition to other warrants to purchase an aggregate of 12,039 shares of common stock at a weighted-average exercise price of $145.11 per share, other options to purchase an aggregate of 80,619 shares of common stock at a weighted-average exercise price of $154.01 per share and $11.0 million of redeemable convertible promissory notes convertible at a rate of $137.85 per share).

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company’s condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company’s financial information. These interim results and cash flows for any interim period are not necessarily indicative of the results to be expected for the full year. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the consolidated financial statements filed with the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 (“Annual Report”). The Company’s significant accounting policies are included in “Part II - Item 8 - Financial Statements and Supplementary Data - Note 2 – Summary of Significant Accounting Policies” in the Company’s Annual Report. There have been no significant changes to these accounting policies during the first three months of 2017.

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2017

Fair Value Disclosures [Abstract]

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following tables present the fair value hierarchy for assets and liabilities measured at fair value on a recurring basis as of March 31, 2017 and December 31, 2016 (in thousands):

	March 31, 2017
	Level 1		Level 2		Level 3		Total
Financial assets:
Money market funds⁽¹⁾	$	14,619		—		—	$	14,619
Restricted cash (money market funds)⁽²⁾		12,860		—		—		12,860
Total financial assets	$	27,479	$	—	$	—	$	27,479

(1)	Included in Cash and Cash Equivalents on accompanying condensed consolidated balance sheets.

(2)	$12.7 million of restricted cash in the Indenture serves as full collateral for the redeemable convertible notes and $125,000 of restricted cash serves as collateral for the Company’s corporate credit card and deposit for its facility lease.

	December 31, 2016
	Level 1		Level 2		Level 3		Total
Financial assets:
Money market funds⁽¹⁾	$	10,156	$	—	$	—	$	10,156
Restricted cash (money market funds)⁽²⁾		19,593		—		—		19,593
U.S. government agency securities⁽³⁾		6,800		—		—		6,800
Total financial assets	$	36,549	$	—	$	—	$	36,549

(1)	Included in Cash and Cash Equivalents on accompanying condensed consolidated balance sheets.

(2)	$19.4 million of restricted cash in the Indenture serves as full collateral for the redeemable convertible notes and $125,000 of restricted cash serves as collateral for the Company’s corporate credit card and deposit for its facility lease.

(3)	Included in Short-Term Investments on accompanying condensed consolidated balance sheets.

Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2017

Investments All Other Investments [Abstract]

Cash Equivalents, Restricted Cash and Short-Term Investments Classified as Available-for-sale Securities

Cash equivalents, restricted cash and short-term investments, all of which are classified as available-for-sale securities, consisted of the following (in thousands):

March 31, 2017	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Money market funds	$	14,619	$	—	$	—	$	14,619
Restricted cash (money market funds)		12,860		—		—		12,860
Total financial assets	$	27,479	$	—	$	—	$	27,479
Classified as:
Cash and cash equivalents							$	14,619
Restricted cash (money market funds)								12,860
							$	27,479

December 31, 2016	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
Money market funds	$	10,156	$	—	$	—		$	10,156
Restricted cash (money market funds)		19,593		—		—			19,593
Corporate notes		6,802		—		(2	)		6,800
Total financial assets	$	36,551	$	—	$	(2	)	$	36,549
Classified as:
Cash and cash equivalents								$	10,156
Restricted cash (money market funds)									19,593
Short-term investments									6,800
								$	36,549

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Stock Based Compensation (Tables)

3 Months Ended

Mar. 31, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Option Activity under Company's Equity Incentive Plans

The following table summarizes stock option activity under the Company’s equity incentive plans, including stock options granted to non-employees, and related information:

	Number of Shares Underlying Outstanding Options			Weighted- Average Exercise Price		Weighted-Average Remaining Contractual Term (Years)
Outstanding — December 31, 2016		140,990		$	127.56		3.93
Options granted		—
Options forfeited		(15,495	)	$	188.73
Outstanding — March 31, 2017		125,495		$	120.00		4.13
Exercisable — March 31, 2017		93,959		$	143.44		2.58
Vested and expected to vest — March 31, 2017		125,495		$	120.00		4.13

Summary of Weighted Average Valuation Assumptions Used to Estimate Fair Value of Employee Stock Options

The fair value of employee stock options was estimated using the following weighted-average assumptions for the three months ended March 31, 2016:

	Three Months Ended March 31,
	2016
Employee Stock Options:
Risk-free interest rate		1.57	%
Expected term (in years)		6.04
Dividend yield		—
Volatility		73.28	%
Weighted-average fair value of stock options granted	$	21.15

Summary of Stock-Based Compensation Recognized

Total stock-based compensation recognized was as follows (in thousands):

	Three Months Ended March 31,
	2017		2016
Research and development	$	20	$	50
General and administrative		100		103
Total stock-based compensation	$	120	$	153

Net Loss per Share (Tables)

3 Months Ended

Mar. 31, 2017

Earnings Per Share [Abstract]

Basic and Diluted Net Loss Per Share

The following table sets forth the computation of the basic and diluted net loss per share during the three months ended March 31, 2017 and 2016 (in thousands, except share and per share data):

	Three Months Ended March 31,
	2017			2016
Net loss, basic and diluted	$	(4,138	)	$	(3,592	)
Weighted-average number of shares used in computing net loss per share, basic and diluted		906,048			762,007
Net loss per share, basic and diluted	$	(4.57	)	$	(4.71	)

Anti-dilutive Security not Included In Diluted per Share Calculations

	March 31,		December 31,
	2017		2016
Options to purchase common stock		125,495		140,990
Common stock warrants		12,039		12,063
Redeemable convertible notes		92,462		140,743
Total		229,996		293,796

Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2017

Commitments And Contingencies Disclosure [Abstract]

Expected Future Lease Payments Under All Operating Leases

Future minimum lease payments under all non-cancelable operating leases as of March 31, 2017, were as follows (in thousands):

	Minimum Lease Payments
2017		561
2018		125
Total future minimum lease payments		686

Other Income (Expense) (Tables)

3 Months Ended

Mar. 31, 2017

Other Income And Expenses [Abstract]

Detail of Other Income/(Expense), Net

The following table shows the detail of other income/(expense), net for the three month periods ended March 31, 2017 and 2016 (in thousands):

	Three Months Ended March 31,
	2017		2016
Change in derivative liability	$	—	$	960
Other Income, net		33		20
Total Other Income/(expense), net	$	33	$	980

Nature of Operations - Additional Information (Detail)				3 Months Ended
Nature of Operations - Additional Information (Detail)	Apr. 12, 2017 USD ($) $ / shares shares	Apr. 03, 2017 USD ($) shares	Feb. 10, 2017 shares	Mar. 31, 2017 USD ($) shares	Feb. 02, 2017 shares	Dec. 31, 2016 shares
Organization and Nature of Operations [Line Items]
Common stock, shares outstanding				1,000,036		801,756
Proceeds from issuance of common stock, net of issuance costs \| $				$ 1,782,000
Capital on Demand Sales Agreement with Jones Trading Institutional Services LLC
Organization and Nature of Operations [Line Items]
Issuance of stock, shares				198,280
Proceeds from issuance of common stock, net of issuance costs \| $				$ 1,800,000
Common Stock
Organization and Nature of Operations [Line Items]
Issuance of stock, shares				198,280
Subsequent Event
Organization and Nature of Operations [Line Items]
Proceeds from issuance of common stock, net of issuance costs \| $	$ 18,700,000
Warrants exercise shares	2,070,000
Warrants exercise price \| $ / shares	$ 5.50
Subsequent Event \| Capital on Demand Sales Agreement with Jones Trading Institutional Services LLC
Organization and Nature of Operations [Line Items]
Issuance of stock, shares		241,600
Proceeds from issuance of common stock, net of issuance costs \| $		$ 3,500,000
Common stock available for sale \| $		$ 0
Subsequent Event \| Common Stock
Organization and Nature of Operations [Line Items]
Issuance of stock, shares	1,470,000
Subsequent Event \| Series A Preferred Stock
Organization and Nature of Operations [Line Items]
Issuance of stock, shares	13,350
Conversion of redeemable convertible notes to common stock	200
Overallotment Option \| Subsequent Event
Organization and Nature of Operations [Line Items]
Warrants exercise shares	270,000
Overallotment Option \| Subsequent Event \| Common Stock
Organization and Nature of Operations [Line Items]
Issuance of stock, shares	540,000
2017 Reverse Stock Split
Organization and Nature of Operations [Line Items]
Reverse stock split, description				On February 10, 2017, the Company effected a reverse stock split of its common stock at a ratio of 1-for-15 (“2017 Reverse Stock Split”). The 2017 Reverse Stock Split was approved by the Company’s stockholders at a special meeting of stockholders held on February 2, 2017. As a result of the 2017 Reverse Stock Split, each 15 pre-split shares of common stock outstanding were automatically combined into one new share of common stock, and the number of outstanding shares of common stock on the date of the split was reduced from approximately 13.0 million shares to approximately 868,000 shares.
Reverse stock split ratio			0.06667
Common stock, shares outstanding			868,000		13,000,000

Assets and Liabilities Measured at Fair Value (Detail) - USD ($)
$ in Thousands

Mar. 31, 2017

Dec. 31, 2016

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets, fair value

$ 27,479

$ 36,549

Money Market Funds

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets, fair value

^[1]

14,619

10,156

Restricted cash (money market funds)

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets, fair value

12,860

^[2]

19,593

^[3]

U.S. Government Agency Securities

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets, fair value

^[4]

6,800

Fair Value, Inputs, Level 1

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets, fair value

27,479

36,549

Fair Value, Inputs, Level 1 | Money Market Funds

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets, fair value

^[1]

14,619

10,156

Fair Value, Inputs, Level 1 | Restricted cash (money market funds)

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets, fair value

$ 12,860

^[2]

19,593

^[3]

Fair Value, Inputs, Level 1 | U.S. Government Agency Securities

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets, fair value

^[4]

$ 6,800

[1]	Included in Cash and Cash Equivalents on accompanying condensed consolidated balance sheets.
[2]	$12.7 million of restricted cash in the Indenture serves as full collateral for the redeemable convertible notes and $125,000 of restricted cash serves as collateral for the Company’s corporate credit card and deposit for its facility lease.
[3]	$19.4 million of restricted cash in the Indenture serves as full collateral for the redeemable convertible notes and $125,000 of restricted cash serves as collateral for the Company’s corporate credit card and deposit for its facility lease.
[4]	Included in Short-Term Investments on accompanying condensed consolidated balance sheets.

Assets and Liabilities Measured at Fair Value (Parenthetical) (Detail) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted cash	$ 12,735,000	$ 19,468,000
Collateral for Redeemable Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted cash	12,700,000	19,400,000
Collateral for Corporate Credit Card and Deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted cash	$ 125,000	$ 125,000

Cash Equivalents, Restricted Cash and Short-Term Investments Classified as Available-for-sale Securities (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 27,479	$ 36,551
Gross Unrealized Losses		(2)
Estimated Fair Value	27,479	36,549
Money Market Funds
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	14,619	10,156
Estimated Fair Value	14,619	10,156
Money Market Funds \| Restricted cash (money market funds)
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	12,860	19,593
Estimated Fair Value	12,860	19,593
Corporate Notes
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		6,802
Gross Unrealized Losses		(2)
Estimated Fair Value		6,800
Cash Equivalents
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value	$ 14,619	10,156
Short-Term Investments
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value		$ 6,800

Financial Instruments - Additional Information (Detail)	3 Months Ended
Financial Instruments - Additional Information (Detail)	Mar. 31, 2017 USD ($)
Fair Value Disclosures [Abstract]
Significant realized gains or losses on available-for-sale securities	$ 0

Redeemable Convertible Notes - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Aug. 19, 2015
Debt Instrument [Line Items]
Gain on extinguishment of redeemable convertible notes	$ 0	$ 85,000
Redeemable convertible notes, redeemed during period	$ 6,752,000	2,807,000
Convertible Notes
Debt Instrument [Line Items]
Convertible notes, total outstanding principal amount			$ 37,000,000
Redeemable convertible notes, conversion per share price	$ 137.85
Convertible notes, maturity date	Feb. 19, 2018
Convertible notes, maturity period	30 months
Redeemable convertible notes, threshold trading days	10 days
Redeemable convertible notes, conversion feature	$ 1,500,000
Redeemable convertible notes, estimated fair value	37,100,000
Redeemable convertible notes, debt discount	1,400,000
Redeemable convertible notes, interest expense	0	$ 0
Redeemable convertible notes, redeemed	24,100,000
Conversion of convertible notes in to common stock, value	300,000
Redeemable convertible notes, redeemed during period	$ 6,700,000
Convertible Notes \| After Reverse Stock Split
Debt Instrument [Line Items]
Redeemable convertible notes, conversion per share price	$ 137.85

Summary of Option Activity under Company's Equity Incentive Plans (Detail) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Number of Shares Underlying Outstanding Options
Number of Shares Underlying Outstanding Options, Beginning Balance	140,990
Number of Shares Underlying Outstanding Options, Options forfeited	(15,495)
Number of Shares Underlying Outstanding Options, Ending Balance	125,495	140,990
Number of Shares Underlying Outstanding Options, Exercisable — March 31, 2017	93,959
Number of Shares Underlying Outstanding Options, Vested and expected to vest — March 31, 2017	125,495
Weighted- Average Exercise Price
Weighted- Average Exercise Price, Beginning Balance	$ 127.56
Weighted- Average Exercise Price, Options forfeited	188.73
Weighted- Average Exercise Price, Ending Balance	120.00	$ 127.56
Weighted- Average Exercise Price, Exercisable — March 31, 2017	143.44
Weighted- Average Exercise Price, Vested and expected to vest — March 31, 2017	$ 120.00
Weighted-Average Remaining Contractual Term (Years)
Weighted-Average Remaining Contractual Term (Years), Outstanding Balance	4 years 1 month 17 days	3 years 11 months 5 days
Weighted-Average Remaining Contractual Term (Years), Exercisable — March 31, 2017	2 years 6 months 29 days
Weighted-Average Remaining Contractual Term (Years), Vested and expected to vest — March 31, 2017	4 years 1 month 17 days

Fair Values of Stock Options Estimated Using Black-Scholes Valuation Model (Detail) - Employee Stock Option	3 Months Ended
	Mar. 31, 2016 $ / shares
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Line Items]
Risk-free interest rate	1.57%
Expected term (in years)	6 years 15 days
Dividend yield	0.00%
Volatility	73.28%
Weighted-average fair value of stock options granted	$ 21.15

Summary of Stock-Based Compensation Recognized (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 120	$ 153
Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	20	50
General and Administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 100	$ 103

Stock Based Compensation - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2017 USD ($) shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock available for future grant	101,304
Shares remaining outstanding	44,704
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized employee stock based compensation expense \| $	$ 1.0
Unrecognized employee stock based compensation expense, period for recognition	2 years 4 months 10 days

Collaborations - Additional Information (Detail) - USD ($)			1 Months Ended	3 Months Ended
	Apr. 02, 2015	Jun. 16, 2013	Mar. 31, 2017	Mar. 31, 2017	Mar. 31, 2016	Dec. 08, 2016
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Contract revenue				$ 271,000	$ 109,000
Pfizer Inc
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Effective termination notice period	60 days
Pfizer Inc \| Collaboration Agreement \| Maximum
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Contingent cash payments upon achievement of clinical, regulatory and commercial milestones						$ 17,500,000
ISU Abxis
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Contract revenue				300,000	100,000
Deferred revenue			$ 300,000	$ 300,000	$ 600,000
Deferred revenue recognition period				4 years
Milestone payment received			$ 200,000
ISU Abxis \| Up Front Payment
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Amount received for research and development process		$ 1,750,000

Basic and Diluted Net Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Earnings Per Share [Abstract]
Net loss, basic and diluted	$ (4,138)	$ (3,592)
Weighted-average number of shares used in computing net loss per share, basic and diluted	906,048	762,007
Net loss per share, basic and diluted	$ (4.57)	$ (4.71)

Anti-dilutive Security not Included In Diluted per Share Calculations (Detail) - shares	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities	229,996	293,796
Options To Purchase Common Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities	125,495	140,990
Common Stock Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities	12,039	12,063
Redeemable Convertible Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities	92,462	140,743

Common Stock - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Mar. 16, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, value of shares issued under sales agreement	$ 2,000	$ 1,000
Net proceeds from sale of common stock	$ 1,782,000
Capital on Demand Sales Agreement with Jones Trading Institutional Services LLC
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares issued under sales agreement	198,280
Common stock weighted average selling price	$ 9.55
Net proceeds from sale of common stock	$ 1,800,000
Commission against additional paid-in capital	$ 100,000
Capital on Demand Sales Agreement with Jones Trading Institutional Services LLC \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, value of shares issued under sales agreement			$ 6,500,000

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	May 20, 2016
Commitments And Contingencies Disclosure [Line Items]
Operating lease expiration date	2018-02
CMC ICOS Biologics, Inc.
Commitments And Contingencies Disclosure [Line Items]
Contractual obligation payments	$ 2.1	$ 3.8

Expected Future Lease Payments Under Operating Leases (Detail) $ in Thousands	Mar. 31, 2017 USD ($)
Commitments And Contingencies Disclosure [Abstract]
2017	$ 561
2018	125
Total future minimum lease payments	$ 686

Detail of Other Income/(Expense), Net (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Other Income And Expenses [Abstract]
Change in derivative liability		$ 960
Other Income, net	$ 33	20
Total Other Income/(expense), net	$ 33	$ 980

Subsequent Events - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands				3 Months Ended
	May 04, 2017	Apr. 12, 2017	Apr. 03, 2017	Mar. 31, 2017	Dec. 31, 2016
Subsequent Event [Line Items]
Proceeds from issuance of common stock, net of issuance costs				$ 1,782
Common stock, shares outstanding				1,000,036	801,756
Preferred stock, shares outstanding				0	0
Options to purchase aggregate shares of common stock				93,959
Options to purchase aggregate shares of common stock, weighted-average exercise price				$ 120.00	$ 127.56
Options to purchase aggregate shares of common stock, weighted-average exercise price				143.44
Redeemable Convertible Promissory Notes
Subsequent Event [Line Items]
Redeemable convertible notes, conversion per share price				$ 137.85
Common Stock
Subsequent Event [Line Items]
Issuance of stock, shares				198,280
Subsequent Event
Subsequent Event [Line Items]
Proceeds from issuance of common stock, net of issuance costs		$ 18,700
Warrants to purchase common stock		2,070,000
Warrants exercise price		$ 5.50
Subsequent Event \| Overallotment Option
Subsequent Event [Line Items]
Warrants to purchase common stock		270,000
Subsequent Event \| Public Offering
Subsequent Event [Line Items]
Warrants exercise price	$ 5.50
Common stock, shares outstanding	4,260,561
Subsequent Event \| Public Offering \| 2015 Stock Incentive Plan
Subsequent Event [Line Items]
Options to purchase aggregate shares of common stock	44,670
Subsequent Event \| Public Offering \| Other Warrants to Purchase Common Stock
Subsequent Event [Line Items]
Warrants exercise price	$ 145.11
Subsequent Event \| Public Offering \| Other Options to Purchase Common Stock
Subsequent Event [Line Items]
Warrants to purchase common stock	12,039
Subsequent Event \| Public Offering \| Other Options to Purchase Common Stock \| 2015 Stock Incentive Plan
Subsequent Event [Line Items]
Options to purchase aggregate shares of common stock	80,619
Options to purchase aggregate shares of common stock, weighted-average exercise price	$ 58.65
Options to purchase aggregate shares of common stock, weighted-average exercise price	$ 154.01
Subsequent Event \| Public Offering \| Redeemable Convertible Promissory Notes
Subsequent Event [Line Items]
Redeemable convertible promissory notes convertible into share	$ 11,000
Redeemable convertible notes, conversion per share price	$ 137.85
Subsequent Event \| Series A Preferred Stock
Subsequent Event [Line Items]
Issuance of stock, shares		13,350
Conversion of redeemable convertible notes to common stock		200
Subsequent Event \| Series A Preferred Stock \| Public Offering
Subsequent Event [Line Items]
Preferred stock, shares outstanding	5,750
Subsequent Event \| Common Stock
Subsequent Event [Line Items]
Issuance of stock, shares		1,470,000
Subsequent Event \| Common Stock \| Overallotment Option
Subsequent Event [Line Items]
Issuance of stock, shares		540,000
Subsequent Event \| Common Stock \| Public Offering
Subsequent Event [Line Items]
Warrants to purchase common stock	2,041,075
Subsequent Event \| Common Stock \| Series A Preferred Stock \| Public Offering
Subsequent Event [Line Items]
Conversion of redeemable convertible notes to common stock	1,150,000
Capital on Demand Sales Agreement with Jones Trading Institutional Services LLC
Subsequent Event [Line Items]
Issuance of stock, shares				198,280
Proceeds from issuance of common stock, net of issuance costs				$ 1,800
Capital on Demand Sales Agreement with Jones Trading Institutional Services LLC \| Subsequent Event
Subsequent Event [Line Items]
Issuance of stock, shares			241,600
Proceeds from issuance of common stock, net of issuance costs			$ 3,500